Catalent, Inc.
Catalent is a leading global Contract Development and Manufacturing Organization (CDMO) and drug delivery/development company, established in 2007 and headquartered in the United States. It is trusted by pharmaceutical, biotechnology, and consumer health companies to accelerate the development, manufacturing, and delivery of innovative products. The company’s broad expertise spans delivery technologies, development science, and multi-modality manufacturing. In the biopharmaceutical CDMO space, Catalent Biologics provides integrated solutions across the entire drug lifecycle, from early-stage development to global commercialisation. Its services are crucial for various modalities, including biologics (such as monoclonal antibodies), specialty products, and advanced therapies like cell and gene therapies and mRNA. Catalent is particularly recognized for its strong expertise in sterile fill/finish, making it a preferred partner for the reliable production of biologics and vaccines. The company’s infrastructure and integrated platforms, like OneBio, are designed to support diverse client needs and accelerate time-to-market for complex biopharma products.
Latest Market Research Report on Biopharmaceutical CDMO Download PDF Brochure Now
Lonza AG
Lonza is one of the world’s most comprehensive and largest Contract Development and Manufacturing Organizations (CDMOs), founded in 1897 and based in Switzerland. It is a long-standing powerhouse in the healthcare industry, serving clients globally across North America, Europe, and Asia Pacific markets. Lonza operates as a CDMO providing extensive development and manufacturing services for multiple therapeutic areas. Its biopharma focus is substantial, covering biologics, small molecules, and advanced therapies, particularly cell and gene therapy manufacturing. The company’s service portfolio encompasses biologics development, commercial manufacturing, and active pharmaceutical ingredient (API) synthesis. Lonza is committed to continuous investment and expansion of its biologics sites, including new drug substance and commercial drug product facilities, to meet the high and growing demand in the biologics and cell therapy sectors. The company’s scientific and regulatory leadership reinforces its credibility among big pharma clients, positioning it as a key partner for next-generation medicine.
Thermo Fisher Scientific (Patheon)
Thermo Fisher Scientific, a globally renowned leader in scientific solutions, operates its Contract Development and Manufacturing Organization (CDMO) services through its Patheon division, making it one of the largest integrated CDMOs worldwide. Patheon offers end-to-end solutions that cover the entire drug development lifecycle, serving companies in the small molecules, biologics, and advanced therapies sectors. Thermo Fisher’s unique strength lies in its deep vertical integration, which seamlessly combines scientific instruments, consumables, and CDMO services under one corporate entity. This provides significant advantages, including a more secure material supply chain, reduced consumable costs, and early access to new technologies. Patheon supports pharmaceutical and biotech companies with manufacturing and development from R&D through to commercial manufacturing, leveraging its robust scientific infrastructure. This integrated approach allows the company to strengthen domestic supply resilience and act as a comprehensive global provider of high-quality CDMO services.
Charles River Laboratories
Charles River Laboratories is a global integrated Contract Research Organization (CRO) and CDMO partner, established in 1947 in the U.S. It is dedicated to accelerating drug development with science-driven solutions, offering support across the entire drug development continuum, from early research to manufacturing and commercialisation. As a biopharmaceutical CDMO, Charles River specializes in providing innovative solutions and services for biopharma products. The company has made strategic investments in advanced therapies, evidenced by the launch of its eXpDNA plasmid platform. This platform is designed to optimize development and manufacturing timelines for plasmid DNA, a critical starting material for gene therapies and viral vectors. By leveraging its integrated expertise spanning both research and manufacturing, Charles River is positioned as a comprehensive partner for biopharmaceutical innovators seeking to streamline their development pathways and bring new, complex therapies to market.
FUJIFILM Diosynth Biotechnologies
FUJIFILM Diosynth Biotechnologies is a subsidiary of FUJIFILM and a prominent Contract Development and Manufacturing Organization (CDMO) specializing in biologics. The company has grown rapidly to become one of the fastest-growing biologics CDMOs, leveraging significant investment in cutting-edge facility expansions, particularly its North Carolina operations, to become a key supplier for top biopharma clients. FUJIFILM Diosynth Biotechnologies focuses on the development and manufacturing of biologics, including complex therapeutic proteins and advanced biopharma products. The company’s commitment to high-quality manufacturing is reinforced by the adoption of advanced automation and data-driven quality monitoring systems to enhance efficiency and maintain premium standards. A notable development is its significant long-term manufacturing agreements, such as a landmark $3 billion partnership with a major pharmaceutical company, underscoring its pivotal role in both the U.S. and global biologics manufacturing supply chain.
WuXi Biologics / WuXi Advanced Therapies
WuXi Biologics is a leading global biologics Contract Development and Manufacturing Organization (CDMO), while its affiliate, WuXi Advanced Therapies, focuses on the high-growth sector of advanced therapies. This family of companies is instrumental in the cell and gene therapy space, offering comprehensive CDMO services designed to bring new biotherapies to market faster. WuXi Advanced Therapies provides essential tools and technologies, including scalable Adeno-Associated Virus (AAV) and lentiviral vector production capabilities, along with advanced cell banking and analytical techniques. Their expertise helps clients navigate the complex development process for next-generation medicines while maintaining strict regulatory compliance. By focusing on fully integrated and tailored development and manufacturing solutions, WuXi supports biopharma partners from the initial research stages through to commercial production, accelerating the development of life-changing cell and gene therapies worldwide.
Samsung Biologics
Samsung Biologics is a major global player in the Contract Development and Manufacturing Organization (CDMO) market, based in South Korea, with a singular focus on biologics manufacturing. The company has aggressively expanded its manufacturing capacity and global footprint through continuous investment in state-of-the-art facilities. Samsung Biologics provides fully integrated, end-to-end CDMO services for biopharma products. This includes expertise across the entire value chain: cell line development, process development, and large-scale commercial manufacturing for various biologics. It is a key global partner for pharmaceutical companies that require reliable, high-quality, and large-scale production of therapeutic proteins, such most notably monoclonal antibodies. The company’s commitment to operational excellence, rapid expansion, and strategic positioning as a major capacity provider solidifies its importance in the global biopharmaceutical manufacturing landscape.
AGC Biologics
AGC Biologics is a Seattle-based biologics Contract Development and Manufacturing Organization (CDMO), formed in 2018 through the unification of several bioscience entities under AGC (formerly Asahi Glass). The company specializes in the development and manufacturing of a diverse range of biologics, including monoclonal antibodies, biosimilars, vaccines, and is a strong competitor in the burgeoning cell and gene therapy space, manufacturing viral vectors and cell therapies. AGC Biologics is already the manufacturing partner for several FDA-approved advanced therapies. It offers a comprehensive portfolio of services designed for speed and precision, supporting clients from preclinical stages to commercial manufacturing across seven global facilities. By offering both mammalian and microbial expression systems, the company provides flexibility and integrated solutions for complex biopharma product lifecycles, and actively seeks partnerships to accelerate timelines for novel therapeutics like mRNA.
Boehringer Ingelheim International GmbH
Boehringer Ingelheim International GmbH, a pharmaceutical giant established in 1885 in Germany, maintains a significant presence in the CDMO market through its dedicated Biopharmaceutical Contract Manufacturing business, often branded as BioXcellence. This service is a core component of the company’s major business areas, leveraging its vast internal expertise as a world-leading research-based pharmaceutical company. Boehringer Ingelheim offers comprehensive CDMO services focusing on mammalian and microbial cell culture technologies for the production of biopharmaceuticals. The company utilizes its long history of experience in drug development and navigating complex global regulatory environments to provide high-quality, reliable manufacturing services for complex biologics, including therapeutic proteins. By integrating its CDMO operations with its deep regulatory know-how, it provides a stable and reputable partnership for companies seeking development and production support for novel biotherapeutic treatments.
Curia Global, Inc.
Curia Global, Inc., formerly known as Albany Molecular Research (AMRI), is a significant global Contract Development and Manufacturing Organization (CDMO) established in 1991. The company offers an integrated suite of services to both the biopharmaceuticals and pharmaceuticals sectors, supporting the entire drug development lifecycle from discovery and early-stage research through to commercial production. For the biopharma industry, Curia provides advanced research and development (R&D) and commercial manufacturing capabilities aimed at accelerating the creation and production of new biopharmaceutical products. By partnering with biotech and pharma companies, Curia helps streamline complex development programs through its global network of facilities across Europe, Asia, and the United States. Its focus on integrated solutions ensures clients receive seamless support, enabling advancements in new biopharmaceutical products with enhanced efficiency and speed.
Latest Market Research Report on Biopharmaceutical CDMO Download PDF Brochure Now